A phase III randomized study of 5‐fluorouracil and cisplatin versus 5‐fluorouracil, doxorubicin, and mitomycin C versus 5‐fluorouracil alone in the treatment of advanced gastric cancer

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Cancer

• Publication date

  1993-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5PMID 8508349
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric cancer: an old lesson revisited.

  1992cited by this paper
• Cisplatin therapy for adenocarcinoma of the stomach.

  1991cited by this paper
• Chemotherapy of advanced gastric cancer: present status, future prospects.

  1988cited by this paper
• Chemotherapy of advanced gastric cancer: present status, future prospects.

  1988cited by this paper
• Chemotherapy and combined modality therapy for locally advanced and metastatic gastric carcinoma.

  1985cited by this paper
• Chemotherapy and combined modality therapy for locally advanced and metastatic gastric carcinoma.

  1985cited by this paper
• A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.

  1985cited by this paper
• Improved complete response rate and survival in advanced head and neck cancer after three‐course induction therapy with 120‐hour 5‐FU infusion and cisplatin

  1985cited by this paper
• Gastric adenocarcinoma--management of the primary disease.

  1985cited by this paper
• Gastric adenocarcinoma--management of the primary disease.

  1985cited by this paper
• The natural history of gastric cancer and prognostic factors influencing survival.

  1984cited by this paper
• Cisplatin.An active drug in the treatment of disseminated gastric cancer

  1984cited by this paper
• Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer.

  1983cited by this paper
• A phase II study of cisplatin in advanced gastric cancer.

  1983cited by this paper
• A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma

  1982cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.

  1980cited by this paper
• cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

  1979cited by this paper
• cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

  1979cited by this paper
• Cis-diamminedichloroplatinum (II). A new anticancer drug.

  1977cited by this paper
• Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5‐FU vs. methyl‐CCNU plus bolus weekly 5‐FU. A southwest oncology group study

  1976cited by this paper
• Reduction of 5-fluorouracil toxicity in man with retention of anticancer effects by prolonged intravenous administration in 5 per cent dextrose.

  1960cited by this paper
• Reduction of 5-fluorouracil toxicity in man with retention of anticancer effects by prolonged intravenous administration in 5 per cent dextrose.

  1960cited by this paper

• Mechanical property changes of glial LC and RGC axons in response to high intraocular pressure

  2025cites this paper
• FAM32A Suppression Decreases 5-Fluorouracil-induced Apoptosis and Is Associated With Poor Prognosis in Gastric Cancer

  2024cites this paper
• 3,3′-Diindolylmethane Augments 5-Fluorouracil-InducedGrowth Suppression in Gastric Cancer Cells through Suppression of the Akt/GSK-3β and WNT/Beta-Catenin

  2023cites this paper
• Cytoreduction and Hyperthermic Intraperitoneal Paclitaxel and Cisplatin for Gastric Cancer with Peritoneal Metastasis

  2023cites this paper
• Growth differentiation factor 15 induces cisplatin resistance through upregulation of xCT expression and glutathione synthesis in gastric cancer

  2023cites this paper
• Chemotherapy Efficacy and Tolerability in Metastatic Gastric Cancer Patients Aged 75 Years and Older

  2023cites this paper
• A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)

  2023cites this paper
• MiR-522-3p Targets Transcription Factor 4 to Overcome Cisplatin Resistance of Gastric Cells

  2022cites this paper
• Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma

  2022cites this paper
• Current Stimuli-Responsive Mesoporous Silica Nanoparticles for Cancer Therapy

  2021cites this paper
• Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment

  2021cites this paper
• Efficacy of Metformin and Chemotherapeutic Agents on the Inhibition of Colony Formation and Shh/Gli1 Pathway: Metformin/Docetaxel Versus Metformin/5-Fluorouracil

  2020cites this paper
• Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy

  2020cites this paper
• Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors

  2020cites this paper
• One-step, Rapid and Green Synthesis of Multifunctional Gold Nanoparticles for Tumor-Targeted Imaging and Therapy

  2020cites this paper
• Present status and perspective of chemotherapy for patients with unresectable advanced or metastatic gastric cancer in Japan.

  2020cites this paper
• Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy

  2020cites this paper
• Leitlinienreport zur S3-Leitlinie Magenkarzinom – „Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs“

  2019cites this paper
• Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

  2019cites this paper
• Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

  2019cites this paper
• Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies

  2019cites this paper
• Comparison of oral capecitabine alone versus platinum combinations in elderly metastatic gastric cancer patients

  2019cites this paper
• Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer

  2019cites this paper
• Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer.

  2019cites this paper
• Systemic Treatment for Metastatic or Recurrent Disease

  2019cites this paper
• A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis

  2019cites this paper
• Outcome Analysis of Cisplatin-5 Flurouracil and Weekly 5-Flurouracil in Advanced Gastric Cancer.

  2019influential citation
• Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).

  2018cites this paper
• Recent trend in gastric cancer treatment in the USA

  2018cites this paper
• Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer

  2018cites this paper
• Activated Integrated Stress Response Induced by Salubrinal Promotes Cisplatin Resistance in Human Gastric Cancer Cells via Enhanced xCT Expression and Glutathione Biosynthesis

  2018cites this paper
• Chapter 3: Surgical Management of Liver Metastases from Gastric Cancer

  2018cites this paper
• Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis.

  2018cites this paper
• Effects of modified FOLFOX-6 chemotherapy on cellular immune function in patients with gastric cancer.

  2018cites this paper
• Gastric Cancer: Chemotherapy for Advanced Disease with Special Focus on Studies from Japan

  2018cites this paper
• Co-operative groups in the development of chemotherapy for gastric cancer.

  2018cites this paper
• A Prospective Phase I/II Study of Docetaxel, Cisplatin and Continuous Capecitabine in Advanced Oesophago-Gastric Cancer (NWCOG-3).

  2018cites this paper
• Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm

  2017cites this paper
• Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents

  2017cites this paper
• Advanced gastric adenocarcinoma: optimizing therapy options

  2017cites this paper
• Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry

  2017cites this paper
• Chemotherapy for advanced gastric cancer.

  2017cites this paper
• Human Scirrhous Gastric Cancer : Chemotherapeutic Trials from Clinical and Basic Approaches 13055

  2017cites this paper
• Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis

  2017cites this paper
• Second-line chemotherapy for patients with advanced gastric cancer

  2017cites this paper
• Feasibility of Modified FOLFOX in Elderly Patients Aged ≥80 Years with Metastatic Gastric Cancer or Colorectal Cancer

  2017cites this paper
• Global chemotherapy development for gastric cancer

  2017cites this paper
• Chapter 47 – Gastric/GE Junction Cancer

  2016cites this paper
• An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups

  2016cites this paper
• Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway

  2016cites this paper
• Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial

  2016cites this paper
• A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction

  2016cites this paper
• The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.

  2016cites this paper
• EF24 induces ROS-mediated apoptosis via targeting thioredoxin reductase 1 in gastric cancer cells

  2016cites this paper
• Outcomes of surgery for gastric cancer with distant metastases: a retrospective study from the SEER database

  2016cites this paper
• A Systematic Review of the Randomised Phase III Clinical Trials Employing Palliative Chemotherapy in the Management of Advanced Esophagogastric Adenocarcinoma

  2016cites this paper
• Is There Any Role of Adjuvant Chemotherapy for T3N0M0 or T1N2M0 Gastric Cancer Patients in Stage II in the 7th TNM but Stage I in the 6th TNM System?

  2016cites this paper
• Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis

  2016cites this paper
• Chemotherapy in Elderly Patients with Gastric Cancer

  2016cites this paper
• The role of surgery in stage IV gastric cancer

  2015cites this paper
• ROS generation mediates the anti-cancer effects of WZ35 via activating JNK and ER stress apoptotic pathways in gastric cancer

  2015cites this paper
• Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

  2015cites this paper
• Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer "The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease".

  2015cites this paper
• Management of gastric cancer: East vs West.

  2015cites this paper
• Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

  2015cites this paper
• Treatment for unresectable gastric cancer

  2015cites this paper
• Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer

  2015cites this paper
• Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis

  2015cites this paper
• A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer

  2015cites this paper
• The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model.

  2015influential citation
• Efficacy of paclitaxel-based doublet regimens combining with intraperitoneal chemotherapy for advanced gastric cancer with peritoneal metastasis.

  2015cites this paper
• A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer

  2014cites this paper
• Chemotherapy for Advanced Gastric Cancer in Elderly Patients

  2014cites this paper
• Full Length Research Article IMPROVING SURVIVAL IN ADVANCED GASTRIC CANCER: A QUALITATIVE APPROACH

  2014cites this paper
• 진행성 노인 위암에 대한 항암요법

  2014cites this paper
• Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.

  2014cites this paper
• Low-dose, short-interval target vessel regional chemotherapy through the hepatic artery combined with transarterial embolization in gastric cancer patients with liver metastases after failure of first-line or second-line chemotherapy: a preliminary analysis

  2014cites this paper
• VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

  2014cites this paper
• Treatment of gastric cancer.

  2014cites this paper
• Efficacy of Intraperitoneal and Intravenous Chemotherapy for Advanced Gastric Cancer with Peritoneal Metastasis

  2014cites this paper
• Chemotherapy of Advanced Gastric Cancer

  2013cites this paper
• Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases

  2013cites this paper
• A phase II study of preoperative chemotherapy with modified FOLFOX6 followed by surgery and postoperative chemoradiation in patients with localized gastric adenocarcinoma.

  2013cites this paper
• Platinum-Based Versus Non-Platinum-Based Chemotherapy as First Line Treatment of Inoperable, Advanced Gastric Adenocarcinoma: A Meta-Analysis

  2013cites this paper
• Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival

  2013cites this paper
• Dose-Dense Regimen of Cisplatin and Infusional Fluorouracil in Advanced Gastric Cancer—A Single Institution Experience

  2013cites this paper
• Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma.

  2013cites this paper
• Retrospective Analysis on the Management of Metastatic Gastric Cancer Patients. A Mono-institutional Experience. What happens in Clinical Practice?

  2013cites this paper
• A Study of Gastric Cancer Cases with Liver Metastasis

  2013cites this paper
• A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.

  2012cites this paper
• Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study

  2012cites this paper
• A Phase III study of combination therapy of the oral fluorinated pyrimidine compound tegafur-uracil (UFT) with low dose cisplatin compared with UFT alone in patients with locally advanced gastric cancer as postoperative adjuvant chemotherapy

  2012cites this paper
• Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen

  2012cites this paper
• Second-line chemotherapy for advanced gastric cancer in Korea

  2012cites this paper
• Recent Advances in Chemotherapy of Gastric Cancer

  2012cites this paper
• Surgical treatment of liver metastases of gastric cancer: state of the art

  2012cites this paper
• Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma

  2012cites this paper
• [Evaluation of the efficacy and toxicity of protocol cisplatin, 5-fluorouracil, leucovorin compared to protocol fluorouracil, doxorubicin and mitomycin C in locally advanced and metastatic gastric cancer].

  2012cites this paper
• Surgical treatment of liver metastases of gastric cancer: is local treatment in a systemic disease worthwhile?

  2012cites this paper
• Chemotherapy for gastric cancer patients – time for personalization in medicine?

  2012cites this paper